Perpetua Medical (PERP) Q3 2024 earnings summary

Executive summary

• Completed first acquisition: 70% of ES-Medical AB, with option for remaining 30% after three years; ES-Medical seen as profitable with growth potential.

• Strategic shift from Pharmacolog to Perpetua Medical, focusing on acquiring profitable healthcare companies.

• Ongoing divestment of WasteLog and completed sale of DrugLog, generating significant one-time gains.

Financial highlights

• Q3 net revenue: 385 KSEK (down 72% year-over-year); 9M net revenue: 2,775 KSEK (down 62%).

• Q3 operating result: -1,166 KSEK (improved from -4,418 KSEK); 9M operating result: -1,351 KSEK (improved from -14,305 KSEK).

• Q3 net result: -1,125 KSEK; 9M net result: -1,117 KSEK.

• Q3 cash flow: -131 KSEK; 9M cash flow: 3,238 KSEK, supported by DrugLog sale and new share issue.

• Cash at period end: 8,771 KSEK; equity: 12,074 KSEK; soliditet: 45%.

Outlook and guidance

• Focus on further acquisitions of profitable healthcare companies and continued cost reductions.

• ES-Medical subsidiary to deliver systems to Karolinska University Hospital post-period.